December 22, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Mandatory notification of trade - primary insider
(Press Release 74/2016). See link for details

December 14, 2016
Nordic Nanovector: - Nordic Nanovector ASA - Registration of share capital increase in the Norwegian Register of Business Enterprises
(Press Release 73/2016). See link for details

December 12, 2016
Nordic Nanovector: - NORDIC NANOVECTOR TO PRESENT AT DNB HEALTHCARE CONFERENCE
(Press Release 72/2016). See link for details

December 9, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Mandatory notification of trade - primary insiders
(Press Release 71/2016). See link for details

December 9, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Mandatory notification of trade - primary insiders
(Press Release 70/2016). See link for details

December 8, 2016
Nordic Nanovector: - Nordic Nanovector management expresses strong confidence in the Company
(Press Release 69/2016). See link for details

December 8, 2016
Nordic Nanovector: - NORDIC NANOVECTOR: RE MANDATORY NOTIFICATION OF TRADE - PRIMARY INSIDER
(Press Release 68/2016). See link for details

December 8, 2016
Nordic Nanovector: - Nordic Nanovector: Mandatory notification of trade - primary insider
(Press Release 67/2016). See link for details

December 7, 2016
Nordic Nanovector: - Nordic Nanovector – Private placement successfully completed
(Press Release 66/2016). See link for details

December 6, 2016
Nordic Nanovector: - Nordic Nanovector launches a private placement of new shares
(Press Release 65/2016). See link for details

December 6, 2016
Nordic Nanovector: - Nordic Nanovector: Betalutin® in combination with rituximab demonstrates synergistic anti-tumour effect in preclinical non-Hodgkin lymphoma model
(Press Release 64/2016). See link for details

December 5, 2016
Nordic Nanovector: - Nordic Nanovector: Single-dose Betalutin® shows promising efficacy, improved duration of response and favourable safety in relapsed NHL patients
(Press Release 63/2016). See link for details

December 4, 2016
Nordic Nanovector: - Nordic Nanovector: Single-dose Betalutin® shows promising efficacy, improved duration of response and favourable safety in relapsed NHL patients
(Press Release 62/2016). See link for details

December 1, 2016
Nordic Nanovector: - Nordic Nanovector to Present at the Nordic-American Life Sciences Conference in New York
(Press Release 61/2016). See link for details

November 23, 2016
Nordic Nanovector: - Nordic Nanovector ASA – Results for third quarter 2016
(Press Release 59/2016). See link for details
See: Q3 REPORT 2016
See: Q3 PRESENTATION 2016

November 23, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA - RESULTATER FOR TREDJE KVARTAL 2016
(Press Release 60/2016). See link for details
See: Q3 REPORT 2016
See: Q3 PRESENTATION 2016

November 16, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Third Quarter 2016 Results Presentation and Webcast
(Press Release 58/2016). See link for details

November 15, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Allotment of share options
(Press Release 57/2016). See link for details

November 15, 2016
Nordic Nanovector: - Nordic Nanovector appoints Dr Lisa Rojkjaer, MD as Chief Medical Officer
(Press Release 56/2016). See link for details

November 14, 2016
Nordic Nanovector: - Nordic Nanovector to Present at Jefferies 2016 London Healthcare Conference
(Press Release 55/2016). See link for details

November 4, 2016
Nordic Nanovector: - Safety Review Committee for Nordic Nanovector’s Lymrit 37-01 trial recommends dose escalation to 20 MBq/kg with Betalutin®
(Press Release 54/2016). See link for details

November 3, 2016
Nordic Nanovector: - Nordic Nanovector: Results from preclinical studies of Betalutin® in combination with rituximab in non-Hodgkin lymphoma model to be presented at ASH
(Press Release 53/2016). See link for details

November 3, 2016
Nordic Nanovector: - Nordic Nanovector: Updated results from Phase 1/2 trial of Betalutin® in non-Hodgkin lymphoma to be presented at ASH annual meeting in December
(Press Release 52/2016). See link for details

October 26, 2016
Nordic Nanovector: - Nordic Nanovector and Heidelberg Pharma enter collaboration to develop novel antibody-drug conjugates (ADCs) targeting leukaemias
(Press Release 51/2016). See link for details

October 20, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Issuance of restricted stock unites (RSUs) to the new board member Joanna Horobin
(Press Release 50/2016). See link for details

October 12, 2016
Nordic Nanovector: - Nordic Nanovector announces the appointment of Joanna Horobin, MD, as Non-executive Board Director
(Press Release 49/2016). See link for details

October 12, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Extraordinary General Meeting held
(Press Release 48/2016). See link for details
See: Nordic Nanovector - Minutes of EGM

October 10, 2016
Nordic Nanovector: - Nordic Nanovector and LegoChem Biosciences enter collaboration to develop novel antibody-drug conjugates (ADCs) targeting leukaemias
(Press Release 47/2016). See link for details

September 23, 2016
Nordic Nanovector: - Safety Review Committee supports dose escalation with Betalutin® in Lymrit 37-01 trial pending safety data from cohort receiving higher pre-dosing
(Press Release 46/2016). See link for details

September 21, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA – CHANGES TO THE BOARD OF DIRECTORS AND NOTICE OF EXTRAORDINARY GENERAL MEETING
(Press Release 45/2016). See link for details
See: NOTICE EGM NORDIC NANOVECTOR
See: Proposal from the nomination committee

September 13, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA –NOTIFICATION OF SHARE CAPITAL INCREASE
(Press Release 44/2016). See link for details

September 5, 2016
Nordic Nanovector: - Lilotomab pre-dosing of NHL patients before Betalutin® therapy lowers haematological toxicity with no reduction in the tumor absorbed radiation dose
(Press Release 43/2016). See link for details

August 31, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA - FINANCIAL CALENDAR
(Press Release 42/2016). See link for details

August 30, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA – MANDATORY NOTIFICATION OF TRADE/ISSUANCE OF NEW SHARES
(Press Release 41/2016). See link for details

August 25, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA – MANDATORY NOTIFICATION OF TRADE
(Press Release 40/2016). See link for details

August 24, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA – RESULTS FOR SECOND QUARTER AND HALF YEAR 2016
(Press Release 38/2016). See link for details
See: Q2 2016 Report
See: Q2 2016 presentation

August 24, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA - RESULTATER FOR ANDRE KVARTAL OG FØRSTE HALVÅR 2016
(Press Release 39/2016). See link for details
See: Q2 2016 Report
See: Q2 2016 presentation

August 18, 2016
Nordic Nanovector: - Nordic Nanovector completes recruitment of the first cohorts of Arm 3 and Arm 4 of expanded Phase 1/2 study of Betalutin® in NHL patients
(Press Release 37/2016). See link for details

August 16, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Second Quarter and First Half 2016 Results Presentation and Webcast
(Press Release 36/2016). See link for details

June 28, 2016
Nordic Nanovector: - Nordic Nanovector and AREVA Med to investigate potential of lead-212 conjugated anti-CD37 antibody for treating leukaemias
(Press Release 35/2016). See link for details

June 10, 2016
Nordic Nanovector: - Pre-dosing NHL patients with HH1 anti-CD37 antibody before Betalutin® increases its pharmacokinetic exposure and reduces its haematological toxicity
(Press Release 34/2016). See link for details

June 3, 2016
Nordic Nanovector: - Nordic Nanovector to present at BIO International Convention on 7 June 2016
(Press Release 33/2016). See link for details

May 31, 2016
Nordic Nanovector: - NORDIC NANOVECTOR CAPITAL MARKETS DAY 2016 TO HIGHLIGHT STRONG PROGRESS TOWARDS VISION OF BECOMING A SIGNIFICANT PLAYER IN HAEMATOLOGICAL CANCERS
(Press Release 32/2016). See link for details

May 30, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Allotment of restricted stock unites (RSUs) to the board of directors
(Press Release 31/2016). See link for details

May 23, 2016
Nordic Nanovector: - NORDIC NANOVECTOR TO HOST CAPITAL MARKETS DAY IN OSLO ON 31 MAY 2016
(Press Release 30/2016). See link for details

May 23, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA: NEW BOARD MEMBERS ELECTED BRINGING FURTHER EXPERTISE IN THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE CANCER THERAPIES
(Press Release 29/2016). See link for details

May 19, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Annual general meeting held
(Press Release 28/2016). See link for details
See: MoM AGM Nordic Nanovector ASA

May 19, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA FIRST QUARTER 2016 RESULTS: STRONG PROGRESS ON ALL PRIORITIES AND EXECUTION ON TRACK
(Press Release 26/2016). See link for details
See: Q1 2016 REPORT
See: Q1 2016 PRESENTATION

May 19, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA RESULTATER FOR FØRSTE KVARTAL 2016: GOD FREMGANG FOR PRIORITERTE AKTIVITETER - GJENNOMFØRING I RUTE
(Press Release 27/2016). See link for details
See: Q1 2016 PRESENTATION
See: Q1 2016 REPORT

May 18, 2016
Nordic Nanovector: - Nordic Nanovector announces first patient enrolled in the last cohort (Arm 4) of expanded Phase 1/2 study of Betalutin® in NHL patients
(Press Release 25/2016). See link for details

May 13, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Proposal from the Nomination Committee to the Annual General Meeting 19 May 2016
(Press Release 24/2016). See link for details
See: Release

May 12, 2016
Nordic Nanovector: - Nordic Nanovector ASA: First Quarter 2016 Results Presentation and Webcast
(Press Release 23/2016). See link for details

May 9, 2016
Nordic Nanovector: - Nordic Nanovector announces an open Investigational New Drug application for new clinical study of Betalutin® in diffuse large B-cell lymphoma
(Press Release 22/2016). See link for details

May 4, 2016
Nordic Nanovector: - Nordic Nanovector announces first patient enrolled in Arm 3 of expanded Phase 1/2 study of Betalutin® in NHL patients
(Press Release 21/2016). See link for details

May 4, 2016
Nordic Nanovector: - Nordic Nanovector to present at BioEquity Europe on 11 May 2016
(Press Release 20/2016). See link for details

April 29, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Share capital increase registered
(Press Release 19/2016). See link for details

April 28, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Notice of Annual General Meeting 2016
(Press Release 18/2016). See link for details
See: AGM Notice including form for registration and proxy

April 21, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Exercise of employee share options and increase of share capital
(Press Release 17/2016). See link for details

April 20, 2016
Nordic Nanovector: - SAVE THE DATE - NORDIC NANOVECTOR CAPITAL MARKETS DAY
(Press Release 16/2016). See link for details

April 18, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Betalutin® continues to show promising efficacy and increasing Duration of Response (DoR)
(Press Release 15/2016). See link for details

April 15, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Betalutin® continues to show promising efficacy and increasing Duration of Response (DoR)
(Press Release 14/2016). See link for details

April 11, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ENTERS COLLABORATION WITH PAUL SCHERRER INSTITUTE TO DEVELOP NEW ANTIBODY RADIONUCLIDE CONJUGATES FOR TREATING LEUKAEMIAS
(Press Release 13/2016). See link for details

April 7, 2016
Nordic Nanovector: - Nordic Nanovector to present at the Swiss Biotech Day on 12 April 2016
(Press Release 12/2016). See link for details

March 18, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA - FINANCIAL CALENDAR
(Press Release 11/2016). See link for details

March 17, 2016
Nordic Nanovector: - Nordic Nanovector publishes Annual Report 2015
(Press Release 10/2016). See link for details
See: Annual Report 2015

March 10, 2016
Nordic Nanovector: - Nordic Nanovector to present at the Carnegie Healthcare Seminar on 17 March 2016
(Press Release 9/2016). See link for details

March 4, 2016
Nordic Nanovector: - NORDIC NANOVECTOR: SHARE OPTIONS GRANTED, INCLUDING OPTIONS TO PRIMARY INSIDERS
(Press Release 8/2016). See link for details

March 1, 2016
Nordic Nanovector: - NANO: LATE-BREAKING ABSTRACT ON BETALUTIN® PHASE 1/2 STUDY ACCEPTED FOR PRESENTATION AT AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING 2016
(Press Release 7/2016). See link for details

February 26, 2016
Nordic Nanovector: - NORDIC NANOVECTOR ASA: FOURTH QUARTER AND FULL YEAR 2015 RESULTS; OPERATIONS ON TRACK
(Press Release 5/2016). See link for details
See: Q4 2015 REPORT
See: Q4 2015 Presentation

February 26, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Resultater for fjerde kvartal og helår 2015; holder fremdriftsplanen
(Press Release 6/2016). See link for details
See: Q4 2015 REPORT
See: Q4 2015 Presentation

February 19, 2016
Nordic Nanovector: - Nordic Nanovector ASA: Fourth Quarter and Full Year 2015 Results Presentation and Webcast
(Press Release 4/2016). See link for details

February 5, 2016
Nordic Nanovector: - Nordic Nanovector to present at the Swiss-Scandinavian Bio-Business seminar on 10 February 2016
(Press Release 3/2016). See link for details

February 1, 2016
Nordic Nanovector: - NORDIC NANOVECTOR AWARDED NOK 15 MILLION FROM THE RESEARCH COUNCIL OF NORWAY TO RESEARCH AND DEVELOP NOVEL TARGETED THERAPEUTICS
(Press Release 2/2016). See link for details

January 8, 2016
Nordic Nanovector: - NORDIC NANOVECTOR TO PRESENT AT THE 8TH ANNUAL BIOTECH SHOWCASE CONFERENCE IN SAN FRANCISCO
(Press Release 1/2016). See link for details